This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.

The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

The preparation of dual functionalized nanoparticles is generally provided along with their application. The dual functionalized nanoparticles provide dual targeting and can effectively pass the blood brain barrier and target brain tissue. The dual targeted and dual responsive nanoparticles are functionalized to include at least two different ligands that are capable of transport across the blood brain barrier. The nanoparticles can be prepared from polymeric materials that can be biocompatible, provide long circulation life in a body, and be successfully ligated to both functionalities by use of acid-sensitive and/or redox potential-sensitive bonds for delivery across the blood brain barrier and delivery of a payload to brain tissue.

The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

A compound or a polymer is claimed. A first formula can be ##STR00001##
wherein X is H, CH.sub.3, CN, phenyl, substituted phenyl, (CH.sub.2).sub.mZ, or phenyl(CH.sub.2).sub.mZ; T is O, N, S or NH; m equals 1 to 20; n equals 1-100; and Z is CN, NH.sub.2, Thiol, OH, or CO.sub.2H. The second formula is: ##STR00002##
wherein X is H, CH.sub.3, CN, phenyl, substituted phenyl, (CH.sub.2).sub.mZ, or phenyl(CH.sub.2).sub.mZ; and Z is CN, NH.sub.2, Thiol, OH, or CO.sub.2H. The third formula is ##STR00003##
wherein: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently: H, CH.sub.3, OH, or a halogen.

The present invention is related to reduced graphene oxide (rGO) nanoplatforms coated with a methacrylate-based copolymer and the methods used in the preparation of these platforms for use as a drug carrier system.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodide, persulfate, and many others, with carboxyl group being preferred. The invention also provides polymer particle produced by the methods of the invention.

Provided herein is are polymeric nanoparticles and polymer-bioactive agent conjugates capable of delivering therapeutic agents to the central nervous system (CNS). Further provided herein is a method of treating diseases with such polymer nanoparticles and polymer-bioactive agents conjugates. Also provided herein is a method of making the polymeric nanoparticles.

A copolymer which includes hydrophilic and hydrophobic blocks, which can form nanoparticles in which a physiologically active substance can be efficiently packaged therein and which are stable under acidic conditions. The hydrophilic segment of the copolymer is composed of polyethylene glycol (PEG) and the hydrophobic segment is composed of polystyrene. The hydrophobic segment has a side chain, and the side chain has ends to which a cyclic nitroxide radical having a radical scavenging function and a trialkoxysilane are covalently bonded.